BioVentrix Revenue and Competitors

Location

$180.7M

Total Funding

Estimated Revenue & Valuation

  • BioVentrix's estimated annual revenue is currently $3M per year.(i)
  • BioVentrix's estimated revenue per employee is $125,500
  • BioVentrix's total funding is $180.7M.

Employee Data

  • BioVentrix has 24 Employees.(i)
  • BioVentrix grew their employee count by -44% last year.

BioVentrix's People

NameTitleEmail/Phone
1
VP Sales, USReveal Email/Phone
2
Senior Director, Clinical Affairs & OperationsReveal Email/Phone
3
Senior Director, Principal Science & Cardiac ImagingReveal Email/Phone
4
Director QAReveal Email/Phone
5
Chief Operating OfficerReveal Email/Phone
6
Chief Financial OfficerReveal Email/Phone
7
Director, Training & EducationReveal Email/Phone
8
Director, Clinical ImagingReveal Email/Phone
9
Director ManufacturingReveal Email/Phone
10
Manager, Therapy Development for the ALIVE Trial,Southeast RegionReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is BioVentrix?

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches. BioVentrix offers benefits to all stakeholders in heart failure: Patient improved survival and QOL by treating the underlying cause of HF less invasively Payor reduced hospitalizations and avoidance of more expensive, highly invasive procedures like transplant and LVAD Provider become a pioneer in heart failure and offer unique solutions to your patients, in the growing and most expensive disease state in the world

keywords:Biotechnology

$180.7M

Total Funding

24

Number of Employees

$3M

Revenue (est)

-44%

Employee Growth %

N/A

Valuation

N/A

Accelerator

BioVentrix News

2014-07-09 - BioVentrix raises $12M for heart attack treatment | MassDevice.com On Call

MASSDEVICE ON CALL — BioVentrix reported a $12.4 million funding round for its Revivent heart failure treatment. San Ramon, Calif.-based BioVentrix said in an equity filing that the equity round, involving 195 unnamed investors, began Jan. 24 and closed today. The company will net about $11.4 ...

2012-11-27 - Device startup treating congestive heart failure patients seeks $4 million

BioVentrix is now trying to effect the same left ventricle functional improvement using an endovascular, transcatheter approach. The company’s board of directors includes Steven Healy, president of Zimmer Spine. Here’s a video of the Revivent Myocardial Anchoring System: Promoted Clinical Ca ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.4M244%N/A
#2
$3.4M24N/AN/A
#3
$2.4M240%N/A
#4
$2.5M259%N/A
#5
$4.3M254%N/A